US Food and Drug Administration Commissioner nominee Robert Califf agreed to take fast and “strong action” to hold pharmaceutical companies accountable for producing the scientific evidence required of accelerated approval drugs if confirmed for a second chance at leading the agency, a 4 February letter from Senate Finance Committee Chair Ron Wyden says.
Califf made the pledge to take action within 30 days of assuming office during a recent meeting with the Democratic senator from Oregon
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?